Press Releases

Press Releases

Date Title Files

Mar 01, 2021

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 25, 2021

Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results

Feb 19, 2021

Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine

Feb 16, 2021

Dynavax to Present at the Cowen 41st Annual Health Care Conference

Feb 11, 2021

Dynavax to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 25, 2021

Feb 08, 2021

Dong Yu, Ph.D., Joins Dynavax as Senior Vice President of Vaccine Research

Feb 04, 2021

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 04, 2021

Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018

Feb 01, 2021

Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government

Feb 01, 2021

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response